Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 1/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.59 |
| ▸ | RECQL | P46063 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | HTR6 | P50406 | 2/20 | 0.52 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.50 |
| ▸ | GFER | P55789 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4356067 | 0.88 | KDM4E (0.59) | IP6K1KDM4EMAPTGAAPTK2B | |
| SCHEMBL10739901 | 0.88 | MAPT (0.59) | IP6K1KDM4EMAPTGAAPTK2B | |
| SCHEMBL1335642 | 0.88 | IP6K1 (0.56) | IP6K1KDM4EMAPTGAAPTK2B | |
| Hydrochloric Acid SCHEMBL3503462 | 0.86 | MAPT (0.58) | IP6K1KDM4EMAPTGAAPTK2B | |
| SCHEMBL5740013 | 0.85 | IP6K1 (0.55) | IP6K1KDM4EMAPTGAAPTK2B | |
| SCHEMBL8976368 | 0.85 | IP6K1 (1.00) | IP6K1KDM4EMAPTGAARECQL | |
| SCHEMBL1414341 | 0.85 | IP6K1 (0.70) | IP6K1KDM4EMAPTGAARECQL | |
| SCHEMBL8871236 | 0.84 | IP6K1 (0.97) | IP6K1KDM4EMAPTGAARECQL | |
| SCHEMBL26088079 | 0.84 | IP6K1 (0.68) | IP6K1KDM4EMAPTGAARECQL | |
| SCHEMBL1558664 | 0.84 | MAPT (0.55) | IP6K1KDM4EMAPTGAAPTK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071601-B2 | Aminoquinoline derivatives and their use as adenosine A3 ligands | SANOFI-AVENTIS (FR) | 2011-12-06 | — | — | US | disclosed |
| US-20110112092-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | disclosed |
| CN-101239945-B | Aminoquinoline derivatives and their use as adenosine a3 ligands | SANOFI AVENTIS | 2011-04-13 | — | — | CN | disclosed |
| US-20110009626-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
| US-7799922-B2 | Aminoquinoline derivatives and their use as adenosine A3 ligands | SANOFI-AVENTIS (FR) | 2010-09-21 | — | — | US | disclosed |
| US-20090247745-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-AVENTIS (FR) | 2009-10-01 | — | — | US | disclosed |
| US-7547696-B2 | Such as 4-methoxy-N-[6-(morpholin-4-yl)-4-benzylamino-3-cyanoquinolin-2-yl]-benzamide; improved solubility | SANOFI-AVENTIS (FR) | 2009-06-16 | — | — | US | disclosed |
| CN-101239945-A | Aminoquinoline derivatives and their use as adenosine a3 ligands | SANOFI AVENTIS (FR) | 2008-08-13 | — | — | CN | disclosed |
| CN-100402501-C | Aminoquinoline derivatives and their use as adenosine A3Use of ligands | SANOFI AVENTIS (FR) | 2008-07-16 | — | — | CN | disclosed |
| EP-1663982-B1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI AVENTIS (FR) | 2007-11-21 | — | — | EP | disclosed |
| US-20060211689-A1 | Aminoquinoline derivatives and their use as adenosine A3 ligands | SANOFI-AVENTIS U.S. LLC (US) | 2006-09-21 | — | — | US | disclosed |
| CN-1829695-A | Aminoquinoline derivatives and their use as adenosine A3Use of ligands | SANOFI AVENTIS (FR) | 2006-09-06 | — | — | CN | disclosed |
| EP-1663982-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | Sanofi-Aventis (FR) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005009969-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-AVENTIS (FR) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211689-A1 | Aminoquinoline derivatives and their use as adenosine A3 ligands | ADORA3, ADORA2A, ADORA1 | IP6K1 1203/4885KDM4E 3817/4885MAPT 1043/4885 |
| US-20090247745-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | ADORA3, ADORA2A, ADORA1 | IP6K1 1203/4885KDM4E 3817/4885MAPT 1043/4885 |
| US-20110112092-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | ADORA3, ADORA2A, ADORA2B | IP6K1 1518/4885KDM4E 4274/4885MAPT 4773/4885 |
| US-20110009626-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | ADORA3, ADORA2A, ADORA2B | IP6K1 782/4885KDM4E 3522/4885MAPT 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.